Jia Zhangke on Jia Zhangke

This volume is an extended dialogue between the internationally acclaimed Chinese filmmaker Jia Zhangke and film scholar Michael Berry in which Jia offers a comprehensive first-hand account of his life, art, and approach to filmmaking

MEFV mutations in systemic JIA

Background: Systemic form of juvenile idiopathic arthritis (JIA) is regarded as an autoinflammatory disease. Certain genetic polymorphisms in genes coding inflammatory proteins have been associated with the disease. On the other hand mutations of the MEFV gene cause a monogenic autoinflammatory disease, Familial Mediterranean Fever (FMF). In a previous study in adult rheumatoid arthritis 3 out of the 25 British patients who developed secondary amyloidosis had a mutation/polymorphism in the MEFV gene. Aim: To analyse whether mutaions in the MEFV gene had an association with systemic JIA. Patients and methods: MEFV mutations were screened in a total of 32 systemic JIA patients. All had been classified as systemic JIA according to the Durban JIA criteria. None had disease characteristics that met the Tel Hashomer criteria for the diagnosis of FMF. Results: 2 carrier for M694V and two patients who were homozygote for MEFV mutations. Both of these patients were among the most severe patients in the group. One had an excellent response to etanercept whereas the other was resistant to anti-TNF and other conventional treatments and had only a partial response to thalidomide. Although the number of severe mutations were increased in this small group of patients with systemic JIA the difference with the Turkish population did not reach statistical significance, but the disease causing mutation (M694V) was significantly high in the patients with systemic JIA(p = 0.02). Conclusion: However, the severe disease course in the aforementioned patients suggest that MEFV mutations may be a modifying genetic factor in systemic JIA.PubMe

El Patrimonio Cultural Subacuático, un tesoro de todos y para todos. Arqueología Subacuática y participación social en la protección del PCS

Introdução á sessão de Património Cultural Subaquático do JIA 2012, Santiago de Compostel

457 - Status of the Resolutions of the Thirteenth Regular Meeting of the IABA and the Twenty-fifth Regular Meeting of the Executive Committee

(DT-489) Avances en el Cumplimiento de las Resoluciones de la XIII Reunión Ordinaria de la JIA-Rev

Capstone 2019 Art and Art History Senior Projects

This booklet profiles Art Senior Projects by Angelique J. Acevedo, Arin Brault, Bailey Harper, Sue Holz, Yirui Jia, Jianrui Li, Annora B. Mack, Emma C. Mugford, Inayah D. Sherry, Jacob H. Smalley, Laura Grace Waters and Laurel J. Wilson. This booklet profiles Art History Senior Projects by Gabriella Bucci, Melissa Casale, Bailey Harper, Erin O\u27Brien and Laura Grace Waters

474 - Status of the Resolutions of the Thirteenth Regular Meeting of the IABA and The Twenty-sixth Regular Meeting of the Executive Committee

(DT-489) Avances en el Cumplimiento de las Resoluciones de la XIII Reunión Ordinaria de la JIA-Rev

Type II Diabetes and its Treatment

Approximately 28.9 million Americans have been diagnosed with type II diabetes (Jia-Haur Hu, Lin, Miller, Nguyen, & Nguyen, 2014). It is a disease that can cause or potentiate numerous comorbidities that negatively affects multiple body systems if left untreated (Jia-Haur Hu, et al., 2014). In 2012, the total estimated cost for treatment of type II diabetes in America was an astronomical $245 billion (Jia-Haur Hu, et al., 2014). Type II diabetes is a result of many cellular processes that lead to insulin resistance resulting in increased blood glucose levels (Jia-Haur Hu, et al., 2014). Treatments for type II diabetes include several different classifications of oral hypoglycemic medications, insulin injections, exercise, and a modified diet (Jia-Haur Hu, et al., 2014). With the number of Americans being diagnosed with type II diabetes on the rise, a strong understanding of the pathophysiology of the disease and its treatments cannot be disregarded